Jamjoom Pharma profit up 22% to SAR 356.5M in 2024; Q4 at SAR 51.6M

25/02/2025 Argaam Exclusive

View other reports

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) posted a net profit of SAR 356.5 million in 2024, rising from SAR 292.4 million a year earlier.

Financials (M)

Item	2023	2024	Change‬
Revenues	1,100.82	1,318.48	19.8 %
Gross Income	703.84	820.50	16.6 %
Operating Income	313.38	381.09	21.6 %
Net Income	292.40	356.52	21.9 %
Average Shares	70.00	70.00	-
Earnings Per Share before unusual items (Riyals)	4.18	5.09	21.9 %
EPS (Riyals)	4.18	5.09	21.9 %

The profit increase was buoyed by 19.8% revenue growth year-on-year (YoY), driven by successful strategic initiatives to expand sales in key markets and therapeutic areas. This growth was supported by the launch of new products and enhanced manufacturing capabilities, thanks to the modern facilities operating in Egypt and Saudi Arabia.

Additionally, the overall expansion in the pharmaceutical market contributed to strong revenue.

Profits from the joint venture in Algeria contributed to the growth in profits, compensating for the negative impact of foreign currencies due to the depreciation of the Egyptian pound.

Current Quarter Comparison (M)

Compared With The

Item	Q4 2023	Q4 2024	Change‬
Revenues	207.86	259.71	24.9 %
Gross Income	118.91	158.51	33.3 %
Operating Income	42.24	54.57	29.2 %
Net Income	44.48	51.60	16.0 %
Average Shares	70.00	70.00	-
Earnings Per Share before unusual items (Riyals)	0.64	0.74	16.0 %
EPS (Riyals)	0.64	0.74	16.0 %

Item	Q3 2024	Q4 2024	Change‬
Revenues	327.58	259.71	(20.7 %)
Gross Income	194.41	158.51	(18.5 %)
Operating Income	95.67	54.57	(43.0 %)
Net Income	94.99	51.60	(45.7 %)
Average Shares	70.00	70.00	-
Earnings Per Share before unusual items (Riyals)	1.36	0.74	(45.7 %)
EPS (Riyals)	1.36	0.74	(45.7 %)

The fourth-quarter earnings jumped 16% to SAR 51.6 million, compared to SAR 44.48 million in the year-ago period.

On a quarterly basis, the company posted a 45.7% decline in Q4 profit from SAR 94.99 million.

Shareholders’ equity, no minority interest, increased to SAR 1.49 billion as of Dec. 31, 2024, compared to SAR 1.40 billion a year earlier.

Attached Documents

View More Financial Results

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Quarterly Actuals vs Estimates 25/02/202525/02/2025

All
Above Expectations
Below Expectations

Company	Estimated	Actual	Change
CARE	69.52	87.19	25.4 %
JAMJOOM PHARMA	55.80	51.60	(7.5 %)
ACWA POWER	419.00	261.17	(37.7 %)
SAUDI CERAMICS	20.00	(88.50)	(542.5 %)

Company	Estimated	Actual	Change
CARE	69.52	87.19	25.4 %

Company	Estimated	Actual	Change
SAUDI CERAMICS	20.00	(88.50)	(542.5 %)
ACWA POWER	419.00	261.17	(37.7 %)
JAMJOOM PHARMA	55.80	51.60	(7.5 %)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

×